US FDA nod for Pfizer's Covid-19 vaccine 'in days' after panel's support

A panel of outside advisers to the FDA on Thursday voted overwhelmingly to endorse emergency use of the vaccine, paving the way for the agency to authorize the shot

Vaccine
Pfizer has asked the two-dose vaccine, developed with German partner BioNTech, be approved for use in people aged 16 to 85
Reuters
1 min read Last Updated : Dec 12 2020 | 2:08 AM IST
The US Food and Drug Administration said on Friday it was working rapidly to issue an emergency use authorisation for Pfizer's Covid-19 vaccine, with the first Americans set to be immunised as early as Monday or Tuesday. US Department of Health and Human Services Secretary Alex Azar said regulatory authorisation should come within days.

A panel of outside advisers to the FDA on Thursday voted overwhelmingly to endorse emergency use of the vaccine, paving the way for the agency to authorize the shot for a country that has lost more than 285,000 lives to Covid-19.  Pfizer has asked the two-dose vaccine, developed with German partner BioNTech, be approved for use in people aged 16 to 85.


The agency has also notified the US Centers for Disease Control and Prevention and Operation Warp Speed so that it can execute the plans for timely vaccine distribution.  The vaccine — shown to be 95% effective in preventing the disease — is already approved in Britain.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccinePfizerUS FDA

Next Story